BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Lantern Pharma

Lantern Pharma logo

Clinical Trials


AI Companies (Drug Discovery)

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action. Lantern also rescues and revitalizes abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent therapy combinations. Our approach, which leverages our RADR™ platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

cancer drug development genetic screen precision oncology


Posts Mentioning This Company

How AI Empowers Biomarker-Driven Clinical Trials

Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving treatments for patients. Unfortunately, the success rate of clinical trials, particularly in the field of oncology, is not as robust as one might hope. In fact, a 2019 study of …

AI Breaches the Barrier Towards Better CNS Drug Discovery

The sphere of oncology continues to grapple with the complex nature of brain and central nervous system (CNS) tumors. Data predicts that in 2023, the United States will witness approximately 24,810 adults and 5,230 children diagnosed with primary brain or spinal cord tumors. When viewed on a global scale, the …

How AI Enables Precision Oncology

Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from the expansion of therapeutic indications and the identification of drug combinations for use in precision oncology, as well the creation of patient response signatures or biomarker profiles that can be …

11 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 3 Upcoming Public Debuts)

According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies.  Some companies are incorporating AI tools …

11 Biopharma Trends to Watch in 2024

2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with the overall industry’s economic performance—it was also a rough year for biopharma overall. There are signs that 2024 might be better …

9 Innovative Life Sciences Companies to Watch in 2024

The biotech and pharmaceutical industries are entering 2024 amid a wave of innovation and technological advancement.  The biopharma field is increasingly influenced by the advent of cutting-edge technologies such as artificial intelligence (AI), organ-on-a-chip systems, and gene editing therapies promising more personalized and precise treatments for a variety of conditions.

9 Notable AI Companies in Clinical Research to Watch in 2023

The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials might fail due to the lack of financing, insufficient enrollment, …

A Parade of AI-driven Biotechs Going Public in 2020-2021

Over 2020-2021 we have seen a remarkable parade of artificial intelligence (AI), focused on discovering novel therapeutics, going public. This reflects a continuing interest in AI as a transformative technology for the pharmaceutical industry and increasing belief in the wave of technology-driven “neo-biotechs”. Here we list some notable companies which …

Artificial Intelligence Yields Early Results in Drug Discovery

A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …